XIE Li-juan1, XIE Xiao-ping2, SUN Zhen-jie1, LU Chun-xue1
1. Institution of Pathogenic Biology, University of South China, Hengyang 421001, China; 2. The First Affiliated Hospital of University of South China, Hengyang 421001, China
Abstract:The ultimate goal of Chlamydia vaccination is to stimulate a combination of humoral, cellular and mucosal immune responses to exert anti-infective protection and decrease the formation of inflammatory pathology. Chlamydia antigen components, alone or in combination with adjuvants, cannot fully stimulate the immune response. However, nanoparticles offer new strategies for chlamydial vaccine design, owing to their unique advantages such as less toxicity, targeted delivery, slow release, resistance to degradation by enzymes, and improved activity and stability. A wide variety of nanomaterials have been applied in the medical field, and some progress has been made in the development of chlamydial nanovaccines. This article provides a brief overview of research progress in the use of liposome nanoparticles and multimeric particles in chlamydial vaccines.
谢丽娟, 谢小平, 孙珍洁, 陆春雪. 衣原体纳米疫苗的研究进展[J]. 中国人兽共患病学报, 2022, 38(1): 48-54.
XIE Li-juan, XIE Xiao-ping, SUN Zhen-jie, LU Chun-xue. Research progress in Chlamydia nanovaccines. Chinese Journal of Zoonoses, 2022, 38(1): 48-54.
[1] Machhi J, Shahjin F, Das S, et al.Nanocarrier vaccines for SARS-CoV-2[J]. Adv Drug Deliv Rev, 2021, 171: 215-239. DOI:10.1016/j.addr.2021.01.002 [2] Zariwala MG, Bendre H, Markiv A, et al.Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery[J]. Int J Nanomedicine, 2018, 13: 5837-5848. DOI:10.2147/IJN.S166901 [3] Hassan UA, Hussein MZ, Alitheen NB, et al.In vitro cellular localization and efficient accumulation of fluorescently tagged biomaterials from monodispersed chitosan nanoparticles for elucidation of controlled release pathways for drug delivery systems[J]. Int J Nanomedicine, 2018, 13: 5075-5095. DOI:10.2147/IJN.S164843 [4] Yu H, Karunakaran KP, Jiang X, et al.Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice[J]. Infect Immun, 2012, 80(4): 1510-1518. DOI:10.1128/IAI.06338-11 [5] Sakai-Kato K, Yoshida K, Izutsu KI.Effect of surface charge on the size-dependent cellular internalization of liposomes[J]. Chem Phys Lipids, 2019, 224: 104726. DOI:10.1016/j.chemphyslip.2019.01.004 [6] 周洋, 耿兴超, 汪巨峰, 等. 疫苗佐剂最新研究进展[J]. 中国新药杂志, 2013, 22(01): 34-42. [7] Malik A, Gupta M, Gupta V, et al.Novel application of trimethyl chitosan as an adjuvant in vaccine delivery[J]. Int J Nanomedicine, 2018, 13: 7959-7970. DOI:10.2147/IJN.S165876 [8] Rodrigues L, Raftopoulos KN, Tandrup Schmidt S, et al.Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein[J]. J Control Release, 2018, 285: 12-22. DOI:10.1016/j.jconrel.2018.06.028 [9] Mulet X, Boyd BJ, Drummond CJ.Advances in drug delivery and medical imaging using colloidal lyotropic liquid crystalline dispersions[J]. J Colloid Interface Sci, 2013, 393: 1-20. DOI:10.1016/j.jcis.2012.10.014 [10] Kaasgaard T, Drummond CJ.Ordered 2-D and 3-D nanostructured amphiphile self-assembly materials stable in excess solvent[J]. Phys Chem Chem Phys, 2006, 8(43): 4957-4975. DOI:10.1039/b609510k [11] Christensen D, Agger EM, Andreasen LV, et al.Liposome-based cationic adjuvant formulations (CAF): Past, present, and future[J]. J Liposome Res, 2009, 19(1): 2-11. DOI:10.1080/08982100902726820 [12] Rose F, Wern JE, Gavins F, et al.A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522[J]. J Control Release, 2018, 271: 88-97. DOI:10.1016/j.jconrel.2017.12.003 [13] Smith Korsholm K, Agger EM, Foged C, et al.The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes[J]. Immunology, 2007, 121(2): 216-226. DOI:10.1111/j.1365-2567.2007.02560.x [14] Geisel RE, Sakamoto K, Russell DG, et al.In vivo activity of released cell wall lipids of mycobacterium bovis bacillus calmette-guerin is due principally to trehalose mycolates[J]. J Immunol, 2005, 174(8): 5007-5015. DOI:10.4049/jimmunol.174.8.5007 [15] Christensen D, Korsholm KS, Andersen P, et al.Cationic liposomes as vaccine adjuvants[J]. Expert Rev Vaccines, 2011, 10(4): 513-521. DOI:10.1586/erv.11.17 [16] Ishikawa E, Ishikawa T, Morita YS, et al.Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle[J]. J Exp Med, 2009, 206(13): 2879-2888. DOI:10.1084/jem.20091750 [17] Schoenen H, Bodendorfer B, Hitchens K, et al.Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate[J]. J Immunol, 2010, 184(6): 2756-2760. DOI:10.4049/jimmunol.0904013 [18] Holten-Andersen L, Doherty TM, Korsholm KS, et al.Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines[J]. Infect Immun, 2004, 72(3): 1608-1617. DOI:10.1128/iai.72.3.1608-1617.2004 [19] Olsen AW, Follmann F, Erneholm K, et al.Protection against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein[J]. J Infect Dis, 2015, 212(6): 978-989. DOI:10.1093/infdis/jiv137 [20] Abraham S, Juel HB, Bang P, et al.Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet Infect Dis, 2019, 19(10): 1091-1100. DOI:10.1016/s1473-3099(19)30279-8 [21] Martin-Bertelsen B, Korsholm KS, Roces CB, et al.Nano-self-assemblies based on synthetic analogues of mycobacterial monomycoloyl glycerol and DDA: supramolecular structure and adjuvant efficacy[J]. Mol Pharm, 2016, 13(8): 2771-2781. DOI:10.1021/acs.molpharmaceut.6b00368 [22] Nicholls EF, Madera L, Hancock REW.Immunomodulators as adjuvants for vaccines and antimicrobial therapy[J]. Ann N Y Acad Sci, 2010, 1213(1): 46-61. DOI:10.1111/j.1749-6632.2010.05787.x [23] Pal S, Tifrea DF, Follmann F, et al.The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge[J]. Vaccine, 2017, 35(13): 1705-1711. DOI:10.1016/j.vaccine.2017.02.020 [24] Andersen CA, Rosenkrands I, Olsen AW, et al.Novel generation mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from Mycobacterium bovis bacillus Calmette-Guerin[J]. J Immunol, 2009, 183(4): 2294-2302. DOI:10.4049/jimmunol.0804091 [25] Korsholm KS, Hansen J, Karlsen K, et al.Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant[J]. Vaccine, 2014, 32(31): 3927-3935. DOI:10.1016/j.vaccine.2014.05.050 [26] Pawar D, Jaganathan KS.Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response[J]. Drug Delivery, 2014, 23(1): 185-194. DOI:10.3109/10717544.2014.908427 [27] Bento D, Staats HF, Goncalves T, et al.Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity[J]. Eur J Pharm Biopharm, 2015, 93: 149-164. DOI:10.1016/j.ejpb.2015.03.024 [28] Dhakal S, Renu S, Ghimire S, et al.Mucosal immunity and protective efficacy of intranasal inactivated influenza vaccine is improved by chitosan nanoparticle delivery in pigs[J]. Front Immunol, 2018, 9: 934. DOI:10.3389/fimmu.2018.00934 [29] Wedmore I, Mcmanus JG, Pusateri AE, et al.A special report on the chitosan-based hemostatic dressing: experience in current combat operations[J]. J Trauma, 2006, 60(3): 655-658. DOI:10.1097/01.ta.0000199392.91772.44 [30] Abd El-Hack ME, El-Saadony MT, Shafi ME, et al. Antimicrobial and antioxidant properties of chitosan and its derivatives and their applications: a review[J]. Int J Biol Macromol, 2020, 164: 2726-2744. DOI:10.1016/j.ijbiomac.2020.08.153 [31] Li Y, Wang C, Sun Z, et al.Simultaneous intramuscular and intranasal administration of chitosan nanoparticles-adjuvanted chlamydia vaccine elicits elevated protective responses in the lung[J]. Int J Nanomedicine, 2019, 14: 8179-8193. DOI:10.2147/ijn.S218456 [32] Wern JE.Simultaneous subcutaneous and intranasal administration of a CAF01-adjuvanted Chlamydia vaccine elicits elevated IgA and protective Th1/Th17 responses in the genital tract[J]. Front Immunol, 2017, 8: 569. DOI:10.3389/fimmu.2017.00569 [33] Jiao H, Yang H, Zheng W, et al.Enhancement of immune responses by co-administration of bacterial ghosts-mediated Neisseria gonorrhoeae DNA vaccines[J]. J Appl Microbiol, 2021, 130(5): 1770-1777. DOI:10.1111/jam.14815 [34] Zuo Z, Zou Y, Li Q, et al.Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge[J]. Sci Rep, 2021, 11(1): 10389. DOI:10.1038/s41598-021-89940-8 [35] Yaghmur A, Glatter O. Characterization and potential applications of nanostructured aqueous dispersions[J]. Adv Colloid Interface Sci, 2009, 147/148: 333-342. DOI:10.1016/j.cis.2008.07.007 [36] Angelova A, Angelov B, Mutafchieva R, et al.Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery[J].Acc Chem Res, 2011, 44(2): 147-156. DOI:10.1021/ar100120v [37] Hu Y, Zhao Z, Ehrich M, et al.Formulation of nanovaccines toward an extended immunity against nicotine[J]. ACS Appl Mater Interfaces, 2021, 13(24): 27972-27982. DOI:10.1021/acsami.1c07049 [38] Silva AL, Soema PC, Slutter B, et al.PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity[J]. Hum Vaccin Immunother, 2016, 12(4): 1056-1069. DOI:10.1080/21645515.2015.1117714 [39] Rose F, Wern JE, Ingvarsson PT, et al.Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: a quality-by-design approach[J]. J Control Release, 2015, 210: 48-57. DOI:10.1016/j.jconrel.2015.05.004 [40] Sahu R, Dixit S, Verma R, et al.A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85∶15 nanoparticles augments CD4(+) effector (CD44(high) CD62L(low)) and memory (CD44(high) CD62L(high)) T-cells in immunized mice[J]. Nanomedicine, 2020, 29: 102257. DOI:10.1016/j.nano.2020.102257 [41] Sahu R, Dixit S, Verma R, et al.Encapsulation of recombinant MOMP in extended-releasing PLGA 85∶15 Nanoparticles confer protective immunity against a Chlamydia muridarum genital challenge and re-challenge[J]. Front Immunol, 2021, 12: 660932. DOI:10.3389/fimmu.2021.660932 [42] Stephen AG, Raval-Fernandes S, Huynh T, et al.Assembly of vault-like particles in insect cells expressing only the major vault protein[J]. J Biol Chem, 2001, 276(26): 23217-23220. DOI:10.1074/jbc.C100226200 [43] Mikyas Y, Makabi M, Raval-Fernandes S, et al.Cryoelectron microscopy imaging of recombinant and tissue derived vaults: localization of the MVP N termini and VPARP[J]. J Mol Biol, 2004, 344(1): 91-105. DOI:10.1016/j.jmb.2004.09.021 [44] Champion CI, Kickhoefer VA, Liu G, et al.A vault nanoparticle vaccine induces protective mucosal immunity[J]. PLoS One, 2009, 4(4): e5409. DOI:10.1371/journal.pone.0005409